4
Changes in Ownership
CYTOKINETICS INC Filed Acc 0001127602-24-024083
EVP Research & Development sold 7,300 shares at an average $56.77 ($414,401)
- EVP Research & Development acquired 5,300 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham EVP Research & Development | 2024-09-17 | Option exercise 10b5-1 | +5,300 | $7.96 | $42,188 | 128,220 | D |
| Malik Fady Ibraham EVP Research & Development | 2024-09-17 | Sale 10b5-1 | −5,300 | $56.77 | $300,881 | 122,920 | D |
| Malik Fady Ibraham EVP Research & Development | 2024-09-17 | Sale 10b5-1 | −2,000 | $56.76 | $113,520 | 120,920 | D |
| Derivatives | |||||||
| Malik Fady Ibraham EVP Research & Development | 2024-09-17 | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 31,800 | D | ||
| Open-market sales · 7,300 sh · avg $56.77 · $414,401 | |||||||
Loading xslF345X05/form4.xml…